Updated on 2025/07/12

写真a

 
KAWAI Hotaka
 
Organization
Faculty of Medicine, Dentistry and Pharmaceutical Sciences Assistant Professor
Position
Assistant Professor
Profile

口腔病理専門医

分子病理専門医

External link

Degree

  • 博士(歯学) ( 岡山大学 )

  • PhD, DDS

Research Areas

  • Life Science / Tumor biology

  • Life Science / Experimental pathology  / 口腔病理

Education

  • 岡山大学 大学院医歯薬学総合研究科 口腔病理学分野    

    2013.4 - 2017.3

      More details

  • 岡山大学 歯学部 歯学科    

    2006.4 - 2012.3

      More details

Research History

  • Columbia University   Research Scholar

    2024.4 - 2025.3

      More details

  • Graduate School of Medicine, Dentistry and Pharmaceutical Sciences   Research Associate Professor

    2023.5

      More details

  • Graduate School of Medicine, Dentistry and Pharmaceutical Sciences   Assistant Professor

    2021.4

      More details

  • Okayama University   Graduate School of Medicine , Dentistry and Pharmaceutical Sciences   Assistant Professor

    2017.6 - 2021.3

      More details

  • Okayama University   Graduate School of Medicine , Dentistry and Pharmaceutical Sciences

    2017.4 - 2017.5

      More details

Committee Memberships

  • 日本臨床口腔病理学会   「若手の集い」企画委員  

    2023   

      More details

  • 日本臨床口腔病理学会   OED診断基準検討委員会 委員  

    2023   

      More details

  • 岡山大学 修士課程学務委員会 学生募集・就職支援部会   サブリーダー  

    2023   

      More details

  • 日本病理学会   学術評議員  

    2022   

      More details

  • インターナショナル歯科衛生専門学校   学校関係者評価委員会 副委員長  

    2022   

      More details

    Committee type:Other

    researchmap

 

Papers

  • Efficacy of Cisplatin–CXCR4 Antagonist Combination Therapy in Oral Cancer Reviewed

    Saori Yoshida, Hotaka Kawai, Yamin Soe, Htoo Shwe Eain, Sho Sanou, Kiyofumi Takabatake, Yohei Takeshita, Miki Hisatomi, Hitoshi Nagatsuka, Junichi Asaumi, Yoshinobu Yanagi

    Cancers   16 ( 13 )   2326 - 2326   2024.6

     More details

    Authorship:Corresponding author   Publishing type:Research paper (scientific journal)   Publisher:MDPI AG  

    Cisplatin is a platinum-based compound that is widely used for treating inoperable oral squamous cell carcinoma (OSCC) in Japan; however, resistance to cisplatin presents a challenge and innovative approaches are required. We aimed to investigate the therapeutic potential of targeting the chemokine receptor CXCR4, which is involved in angiogenesis and tumor progression, using the CXCR4 inhibitor AMD3100, in combination with cisplatin. AMD3100 induced necrosis and bleeding in OSCC xenografts by inhibiting angiogenesis. We investigated the combined ability of AMD3100 plus cisplatin to enhance the antitumor effect in cisplatin-resistant OSCC. An MTS assay identified HSC-2 cells as cisplatin-resistant cells in vitro. Mice treated with the cisplatin-AMD combination exhibited the most significant reduction in tumor volume, accompanied by extensive hemorrhage and necrosis. Histological examination indicated thin and short tumor vessels in the AMD and cisplatin–AMD groups. These results indicated that cisplatin and AMD3100 had synergistic antitumor effects, highlighting their potential for vascular therapy of refractory OSCC. Antitumor vascular therapy using cisplatin combined with a CXCR4 inhibitor provides a novel strategy for addressing cisplatin-resistant OSCC.

    DOI: 10.3390/cancers16132326

    researchmap

  • Double-faced CX3CL1 enhances lymphangiogenesis-dependent metastasis in an aggressive subclone of oral squamous cell carcinoma. Reviewed International journal

    Htoo Shwe Eain, Hotaka Kawai, Masaaki Nakayama, May Wathone Oo, Toshiaki Ohara, Yoko Fukuhara, Kiyofumi Takabatake, Quisheng Shan, Yamin Soe, Kisho Ono, Keisuke Nakano, Nobuyoshi Mizukawa, Seiji Iida, Hitoshi Nagatsuka

    JCI insight   9 ( 10 )   2024.5

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Because cancer cells have a genetically unstable nature, they give rise to genetically different variant subclones inside a single tumor. Understanding cancer heterogeneity and subclone characteristics is crucial for developing more efficacious therapies. Oral squamous cell carcinoma (OSCC) is characterized by high heterogeneity and plasticity. On the other hand, CX3C motif ligand 1 (CX3CL1) is a double-faced chemokine with anti- and pro-tumor functions. Our study reported that CX3CL1 functioned differently in tumors with different cancer phenotypes, both in vivo and in vitro. Mouse OSCC 1 (MOC1) and MOC2 cells responded similarly to CX3CL1 in vitro. However, in vivo, CX3CL1 increased keratinization in indolent MOC1 cancer, while CX3CL1 promoted cervical lymphatic metastasis in aggressive MOC2 cancer. These outcomes were due to double-faced CX3CL1 effects on different immune microenvironments indolent and aggressive cancer created. Furthermore, we established that CX3CL1 promoted cancer metastasis via the lymphatic pathway by stimulating lymphangiogenesis and transendothelial migration of lymph-circulating tumor cells. CX3CL1 enrichment in lymphatic metastasis tissues was observed in aggressive murine and human cell lines. OSCC patient samples with CX3CL1 enrichment exhibited a strong correlation with lower overall survival rates and higher recurrence and distant metastasis rates. In conclusion, CX3CL1 is a pivotal factor that stimulates the metastasis of aggressive cancer subclones within the heterogeneous tumors to metastasize, and our study demonstrates the prognostic value of CX3CL1 enrichment in long-term monitoring in OSCC.

    DOI: 10.1172/jci.insight.174618

    PubMed

    researchmap

  • Enzyme-Cleaved Bone Marrow Transplantation Improves the Engraftment of Bone Marrow Mesenchymal Stem Cells. Reviewed International journal

    Hotaka Kawai, May Wathone Oo, Kiyofumi Takabatake, Ikue Tosa, Yamin Soe, Htoo Shwe Eain, Sho Sanou, Shigeko Fushimi, Shintaro Sukegawa, Keisuke Nakano, Takarada Takeshi, Hitoshi Nagatsuka

    JBMR plus   7 ( 3 )   e10722   2023.3

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Mesenchymal stem cell (MSC) therapy is a promising approach to curing bone diseases and disorders. In treating genetic bone disorders, MSC therapy is local or systemic transplantation of isolated and in vitro proliferated MSC rather than bone marrow transplantation. Recent evidence showed that bone marrow MSC engraftment to bone regeneration has been controversial in animal and human studies. Here, our modified bone marrow transplantation (BMT) method solved this problem. Like routine BMT, our modified method involves three steps: (i) isolation of bone marrow cells from the donor, (ii) whole-body lethal irradiation to the recipient, and (iii) injection of isolated bone marrow cells into irradiated recipient mice via the tail vein. The significant modification is imported at the bone marrow isolation step. While the bone marrow cells are flushed out from the bone marrow with the medium in routine BMT, we applied the enzymes' (collagenase type 4 and dispase) integrated medium to wash out the bone marrow cells. Then, cells were incubated in enzyme integrated solution at 37°C for 10 minutes. This modification designated BMT as collagenase-integrated BMT (c-BMT). Notably, successful engraftment of bone marrow MSC to the new bone formation, such as osteoblasts and chondrocytes, occurs in c-BMT mice, whereas routine BMT mice do not recruit bone marrow MSC. Indeed, flow cytometry data showed that c-BMT includes a higher proportion of LepR+, CD51+, or RUNX2+ non-hematopoietic cells than BMT. These findings suggested that c-BMT is a time-efficient and more reliable technique that ensures the disaggregation and collection of bone marrow stem cells and engraftment of bone marrow MSC to the recipient. Hence, we proposed that c-BMT might be a promising approach to curing genetic bone disorders. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

    DOI: 10.1002/jbm4.10722

    PubMed

    researchmap

  • SOD3 Expression in Tumor Stroma Provides the Tumor Vessel Maturity in Oral Squamous Cell Carcinoma. Reviewed International journal

    May Wathone Oo, Hotaka Kawai, Htoo Shwe Eain, Yamin Soe, Kiyofumi Takabatake, Sho Sanou, Qiusheng Shan, Yasunori Inada, Masae Fujii, Yoko Fukuhara, Ziyi Wang, Shintaro Sukegawa, Mitsuaki Ono, Keisuke Nakano, Hitoshi Nagatsuka

    Biomedicines   10 ( 11 )   2022.10

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Tumor angiogenesis is one of the hallmarks of solid tumor development. The progressive tumor cells produce the angiogenic factors and promote tumor angiogenesis. However, how the tumor stromal cells influence tumor vascularization is still unclear. In the present study, we evaluated the effects of oral squamous cell carcinoma (OSCC) stromal cells on tumor vascularization. The tumor stromal cells were isolated from two OSCC patients with different subtypes: low invasive verrucous squamous carcinoma (VSCC) and highly invasive squamous cell carcinoma (SCC) and co-xenografted with the human OSCC cell line (HSC-2) on nude mice. In comparison, the CD34+ vessels in HSC-2+VSCC were larger than in HSC-2+SCC. Interestingly, the vessels in the HSC-2+VSCC expressed vascular endothelial cadherin (VE-cadherin), indicating well-formed vascularization. Our microarray data revealed that the expression of extracellular superoxide dismutase, SOD3 mRNA is higher in VSCC stromal cells than in SCC stromal cells. Moreover, we observed that SOD3 colocalized with VE-cadherin on endothelial cells of low invasive stroma xenograft. These data suggested that SOD3 expression in stromal cells may potentially regulate tumor vascularization in OSCC. Thus, our study suggests the potential interest in SOD3-related vascular integrity for a better OSCC therapeutic strategy.

    DOI: 10.3390/biomedicines10112729

    PubMed

    researchmap

  • Cancer-Associated Stromal Cells Promote the Contribution of MMP2-Positive Bone Marrow-Derived Cells to Oral Squamous Cell Carcinoma Invasion. Reviewed International journal

    May Wathone Oo, Hotaka Kawai, Kiyofumi Takabatake, Qiusheng Shan, Htoo Shwe Eain, Shintaro Sukegawa, Keisuke Nakano, Hitoshi Nagatsuka

    Cancers   14 ( 1 )   2021.12

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Tumor stromal components contribute to tumor development and invasion. However, the role of stromal cells in the contribution of bone marrow-derived cells (BMDCs) in oral squamous cell carcinoma (OSCC) invasion is unclear. In the present study, we created two different invasive OSCC patient-derived stroma xenografts (PDSXs) and analyzed and compared the effects of stromal cells on the relation of BMDCs and tumor invasion. We isolated stromal cells from two OSCC patients: less invasive verrucous OSCC (VSCC) and highly invasive conventional OSCC (SCC) and co-xenografted with the OSCC cell line (HSC-2) on green fluorescent protein (GFP)-positive bone marrow (BM) cells transplanted mice. We traced the GFP-positive BM cells by immunohistochemistry (IHC) and detected matrix metalloproteinase 2 (MMP2) expression on BM cells by double fluorescent IHC. The results indicated that the SCC-PDSX promotes MMP2-positive BMDCs recruitment to the invasive front line of the tumor. Furthermore, microarray analysis revealed that the expressions of interleukin 6; IL-6 mRNA and interleukin 1 beta; IL1B mRNA were higher in SCC stromal cells than in VSCC stromal cells. Thus, our study first reports that IL-6 and IL1B might be the potential stromal factors promoting the contribution of MMP2-positive BMDCs to OSCC invasion.

    DOI: 10.3390/cancers14010137

    PubMed

    researchmap

▼display all

Books

  • Chaperones

    Hotaka Kawai, Kisho Ono, Takanori Eguchi( Role: Contributor ,  Multiplex Immunostaining Method to Distinguish HSP Isoforms in Cancer Tissue Specimens. pp281-291)

    Humana, New York, NY  2023.8  ( ISBN:9781071633427

     More details

MISC

  • Pseudohypoxia by HIF-PHD inhibitors activates tumor immune response for MSS colorectal cancer

    Toshiaki Ohara, Yuehua Chen, Yusuke Hamada, Seitaro Nishimura, Hotaka Kawai, Kazuhiro Noma, Hiroshi Tazawa, Toshiyoshi Fujiwara, Akihiro Matsukawa

    CANCER RESEARCH   84 ( 6 )   2024.3

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    DOI: 10.1158/1538-7445.AM2024-5271

    Web of Science

    researchmap

  • Effect of CCN2 secreted by ameloblastoma on bone resorption through tumor stroma.

    武部祐一郎, 辻極秀次, 高畠清文, 稲田靖則, 藤井昌江, 河合穂高, 中野敬介, 長塚仁

    日本口腔腫瘍学会総会・学術大会プログラム・抄録集   41st   2023

  • ハニカム構造を有するTCPを応用した骨髄組織誘導

    稲田靖則, 高畠清文, 辻極秀次, 河合穂高, 中野敬介, 長塚仁

    日本口腔科学会学術集会プログラム・抄録集   77th   2023

  • HIF-1αを介したエナメル上皮腫開窓術作用機序の解明

    高畠清文, 稲田靖則, 藤井昌江, 河合穂高, 中野敬介

    日本口腔科学会学術集会プログラム・抄録集   77th   2023

  • A case of multiple neurogenic tumors discovered with buccal mucosa schwannoma

    久富美紀, 竹下洋平, 河合穂高, 岡田俊輔, 藤倉満美子, 吉田沙織, 河津俊幸, 長塚仁, 柳文修, 柳文修, 浅海淳一, 浅海淳一

    日本口腔腫瘍学会総会・学術大会プログラム・抄録集   41st   2023

▼display all

Presentations

  • Double-faced CX3CL1 enhances lymphangiogenesis-dependent metastasis in an aggressive subclone of oral squamous cell carcinoma Invited

    Hotaka Kawai

    Ichan School of Medicine at Mount Sinai, Andrew Lab research seminar  2025.2.10 

     More details

    Presentation type:Oral presentation (invited, special)  

    researchmap

  • Variable Cytokine Dynamics Within Tissues: What Happens in the Heterogeneous Microenvironment of Cancer Invited

    Hotaka Kawai

    Japanese Association of Scholars in Science  2024.9.10 

     More details

    Presentation type:Oral presentation (invited, special)  

    researchmap

  • 未来へのキャリアパス 10年後に目指す歯科医師像を考えよう Invited

    河合穂高

    兵庫県病院歯科医会主催 第8回歯科医師臨床研修医 交流会 サマーキャンプ  2023.7.22 

     More details

    Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • 口腔病理医の視点から見た口腔癌微小環境の不均一性 Invited

    河合穂高

    第41回口腔腫瘍学会 ワークショップ「若手研究者に聞く基礎研究のススメ」  2023.1.27 

     More details

  • Distribution of bone marrow-derived cells in highly metastatic organs. Invited

    Hotaka Kawai

    The first international symposium of Intercellular communication and extracellular vesicles (ICEV-1)  2019.10 

     More details

    Language:English   Presentation type:Symposium, workshop panel (nominated)  

    researchmap

▼display all

Industrial property rights

  • 組織再生用材料及びその製造方法

    河合 穂高, 寳田 剛志, 長塚 仁

     More details

    Applicant:国立大学法人 岡山大学

    Application no:特願2020-168891  Date applied:2020.10.6

    Announcement no:特開2022-061114  Date announced:2022.4.18

    J-GLOBAL

    researchmap

Awards

  • 奨励賞 (実験病理学部門)

    2024.8   日本臨床口腔病理学会  

    河合穂高

     More details

  • 優秀論文賞

    2023.12   岡山歯学会  

    河合穂高

     More details

  • 岡山芸術文化賞 準グランプリ

    2023.8   岡山県  

    河合穂高

     More details

  • 日本口腔科学会 学会賞 優秀ポスター賞

    2023.5   日本口腔科学会  

    河合穂高

     More details

  • 優秀ポスター賞 日本口腔腫瘍学会

    2022.1  

    河合穂高

     More details

▼display all

Research Projects

  • 長期生着MSCを用いた骨形成不全症の新規細胞治療法の開発

    2025.07 - 2027.07

    公益財団法人 武田科学振興財団  医学系研究助成(基礎) 

    河合穂高

      More details

    Authorship:Principal investigator 

    researchmap

  • 実臨床に即した間葉系幹細胞nicheを伴う自家骨移植デバイスの開発

    2025.04 - 2028.03

    公益財団法人NSKナカニシ財団  2025年度研究開発助成 

    河合穂高

      More details

    Authorship:Principal investigator 

    researchmap

  • 骨髄由来間葉系幹細胞を起点とした新たな口腔癌転移メカニズムの解明

    Grant number:24K13130  2024.04 - 2028.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    河合 穂高

      More details

    Grant amount:\4680000 ( Direct expense: \3600000 、 Indirect expense:\1080000 )

    researchmap

  • iRGDによる新規DDSを利用した難治性口腔癌新規抗腫瘍・抗転移治療の開発

    2024.04 - 2025.03

    公益財団法人 寺岡記念育英会  海外留学滞在費助成事業 

    河合穂高

      More details

    Authorship:Principal investigator 

    researchmap

  • iRGDによる微小環境の動態変化を利用した口腔癌の新規抗腫瘍・抗転移治療の開発

    Grant number:22KK0275  2023.04 - 2026.03

    日本学術振興会  科学研究費助成事業 国際共同研究加速基金(国際共同研究強化(A)) 

    河合 穂高

      More details

    Grant amount:\15470000 ( Direct expense: \11900000 、 Indirect expense:\3570000 )

    researchmap

▼display all

Other research activities

 

Class subject in charge

  • Human pathology (2024academic year) 1st semester  - 火5,火6,火7

  • Oral pathology (2024academic year) Second semester  - 火5,火6,火7

  • Practicals: Oral Pathology and Medicine (2024academic year) special  - その他

  • Oral pathology practice (2024academic year) Second semester  - 水4,水5,水6,水7

  • Research Projects: Oral Pathology and Medicine (2024academic year) special  - その他

▼display all

 

Social Activities

  • 世田谷パブリックシアター主催公演『う蝕』歯科監修

    Role(s):Advisor

    世田谷パブリックシアター  2024.2.10 - 2024.3.3

     More details

    Type:Other

    researchmap

  • 口腔病理診断(動物)コンサルテーション

    Role(s):Advisor

    2024.1

     More details

    Type:Other

    researchmap

  • たつのアート2023特別企画「癌と演劇 Inside of Kawai Hotaka」

    Role(s):Appearance

    たつのアート実行委員会  2023.9.10

     More details

    Type:Seminar, workshop

    researchmap

Media Coverage

  • 「骨の元になる細胞」10分で多量に採取 新技術を開発 TV or radio program

    テレビ朝日  ABEMAニュース、テレ朝ニュース  2023.4

     More details

    Author:Other 

    researchmap

  • 間質細胞が免疫抑制細胞呼び寄せ 口腔がん、岡山大河合助教ら確認 Newspaper, magazine

    山陽新聞  山陽新聞 (10/16山陽26第2全県)  2022.10

     More details

    Author:Myself 

    researchmap

  • ガンを兵糧攻め? 新たな抗腫瘍治療の開発 TV or radio program

    NHK岡山放送局  おはよう岡山  2019.10

     More details

Academic Activities

  • 令和5年度 和歌山県立医科大学 薬学部 特別講義「がん・化学療法学」口腔癌・口腔癌治療の概説

    和歌山県立医科大学 薬学部  2023.7.11

     More details